A Study Comparing Shared Solutions® Plus MS Center Support Versus Shared Solutions® Alone

Teva Pharmaceuticals

Status and phase

Completed

Phase 4

Conditions

Multiple Sclerosis

Treatments

Procedure: Shared Solutions® plus MS Center v. Shared Solutions®

Study type

Interventional

Funder types

Industry

Identifiers

NCT00240006

PM024

Details and patient eligibility

About

To compare the effectiveness of a 90-day Copaxone® adherence enhancement program for a sample of MS patients who are at high risk of nonadherence and receive support from Shared Solutions® and their MS Center versus those who receive support only from Shared Solutions®.

Enrollment

307 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Males or females, 18 years of age or older.
Diagnosed with Relapsing Remitting Multiple Sclerosis (relapses accepted).
Beginning or restarting therapy with Glatiramer Acetate (Copaxone®).
Willing and able to complete all procedures and evaluations related to the study.
Willing to provide informed consent.

Exclusion criteria

Taking any other immunomodulatory or immunosuppressant therapy in conjunction with Copaxone®.
Has a significant medical illness other than MS that may interfere with the assessment of endpoints or the subject's participation in the trial for the full duration of the study.
Any situation that the investigator or nurse (if not the investigator) feel may interfere with participation in the study.
Pregnant or trying to become pregnant, or breast feeding during the study.
Previously participated in this study or another clinical research study in the past 30 days.